Streetbeat News

Analyst Ratings

PRFT

JP Morgan analyst Puneet Jain has downgraded Perficient (NASDAQ:PRFT) from Overweight to Neutral and lowered the price target from $84 to $70.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:35 am

FIXX

Baird analyst Madhu Kumar has downgraded Homology Medicines (NASDAQ:FIXX) from Outperform to Neutral and lowered the price target from $9 to $1.5.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:33 am

TSVT

Morgan Stanley analyst Matthew Harrison has downgraded 2seventy bio (NASDAQ:TSVT) from Overweight to Equal-Weight and lowered the price target from $25 to $13.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:31 am

MRSN

Baird analyst Colleen Kusy has downgraded Mersana Therapeutics (NASDAQ:MRSN) from Outperform to Neutral and lowered the price target from $7 to $1.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:30 am

HZO

B. Riley Securities has downgraded MarineMax (NYSE:HZO) from Buy to Neutral and lowered the price target from $48 to $43.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:30 am

LUV

Deutsche Bank analyst Michael Linenberg has downgraded Southwest Airlines (NYSE:LUV) from Buy to Hold and lowered the price target from $52 to $38.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:28 am

TGH

Keefe, Bruyette & Woods analyst Michael Brown has downgraded Textainer Gr Hldgs (NYSE:TGH) from Outperform to Market Perform, but raised the price target from $40 to $45.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:26 am

FMAO

Piper Sandler analyst Brendan Nosal has downgraded Farmers & Merchants (NASDAQ:FMAO) from Neutral to Underweight and lowered the price target from $24 to $23.5.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:25 am

BFST

Raymond James analyst Daniel Tamayo has upgraded Business First Bancshares (NASDAQ:BFST) from Market Perform to Outperform and set a price target of $20.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:23 am

CLS

RBC Capital analyst Maxim Matushansky has upgraded Celestica (NYSE:CLS) from Sector Perform to Outperform and raised the price target from $14 to $22.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 9:23 am